Lv41
460 积分 2025-07-01 加入
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
22分钟前
待确认
Survival outcome comparison of neoadjuvant and perioperative ICI-based therapies in patients with non-small cell lung cancer achieving MPR or pCR: a systematic review and meta-analysis
1小时前
已完结
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
1小时前
已完结
New strategies for patients with limited-stage small-cell lung cancer
20天前
已完结
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies
1个月前
已完结
Maintenance Chemotherapy for Nonsmall Cell Lung Cancer
1个月前
已完结
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
1个月前
已完结
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
1个月前
已完结
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
1个月前
已完结
Rapid Advances in Resectable Non–Small Cell Lung Cancer
1个月前
已完结
皖公网安备34019202002308
